Article
FDA accepts new drug application for low-dose atropine from Sydnexis
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain
Luxa Biotechnology presents clinical data from the phase 1/2a trial evaluating RPESC-RPE-4W